Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN) – (Studies 105 and 106)

Phase 2/3 Neutropenia Prevention with Docetaxel

Phase 2/3 Trial for Solid Tumors in which Docetaxel is Approved

The Phase 2/3 trial of Plinabulin with Docetaxel in patients treated with Docetaxel in all solid tumor indications will evaluate the combination for the prevention of Febrile Neutropenia induced by Docetaxel. The Phase 2 study demonstrated solid efficacy in reducing Neutropenia in patients previously treated with docetaxel and displayed a strong safety profile. These results provided a strong basis to initiate the Phase 2/3 study.

The multi-center, randomized, open label trial plans to enroll approximately 100 patients in each arm for a three-month long study.

Study Design and Status


More Information

More information on this pivotal trial is available on